Next Article in Journal
Special Issue: Fungal Cell Wall
Next Article in Special Issue
Treatment of Invasive Candidiasis: A Narrative Review
Previous Article in Journal
Immunopathogenesis of Human Sporotrichosis: What We Already Know
Previous Article in Special Issue
Treatment of Infections Due to Aspergillus terreus Species Complex
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
J. Fungi 2018, 4(3), 90; https://doi.org/10.3390/jof4030090

Therapy of Mucormycosis

1
Pathophysiology Department, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, 115 27 Athens, Greece
2
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
Received: 15 July 2018 / Revised: 28 July 2018 / Accepted: 30 July 2018 / Published: 31 July 2018
(This article belongs to the Special Issue Treatments for Fungal Infections)
Full-Text   |   PDF [408 KB, uploaded 1 August 2018]   |  

Abstract

Despite the recent introduction of mold-active agents (posaconazole and isavuconazole), in addition to amphotericin B products, to our armamentarium against mucormycosis, many uncertainties remain for the management of this uncommon opportunistic infection, as there are no data from prospective randomized clinical trials to guide therapy. In this mini-review, we present the current status of treatment options. In view of the heterogeneity of the disease (different types of affected hosts, sites of infection, and infecting Mucorales), mucormycosis management requires an individualized management plan that takes into account the net state of immunosuppression of the host, including comorbidities, certainty of diagnosis, site of infection, and antifungal pharmacological properties. View Full-Text
Keywords: mucormycosis; treatment; amphotericin B; posaconazole; isavuconazole; surgery; leukemia; stem cell transplantation mucormycosis; treatment; amphotericin B; posaconazole; isavuconazole; surgery; leukemia; stem cell transplantation
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Sipsas, N.V.; Gamaletsou, M.N.; Anastasopoulou, A.; Kontoyiannis, D.P. Therapy of Mucormycosis. J. Fungi 2018, 4, 90.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Fungi EISSN 2309-608X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top